Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.4K
Epigenetic Regulation01:37

Epigenetic Regulation

4.3K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.3K
Epigenetic Regulation01:46

Epigenetic Regulation

34.5K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.5K
Epigenetic Regulation01:46

Epigenetic Regulation

26.3K
26.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

10.1K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beckwith-Wiedemann syndrome multiomic analysis of hepatoblastoma uncovers unique tumour heterogeneity and cellular landscapes, including transition cells leading to tumour formation.

BJC reports·2026
Same author

Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples.

Molecular cell·2026
Same author

Correlates of head-fixed directional forelimb movements in mouse superior colliculus and substantia nigra pars reticulata.

Neuroscience·2026
Same author

Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Blood cancer discovery·2025
Same author

Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.

HemaSphere·2025

Related Experiment Video

Updated: Apr 13, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Epigenetic modifiers in normal and malignant hematopoiesis.

Jessica N Haladyna1, Taylor Yamauchi, Tobias Neff

  • 1Division of Pediatric Hematology/Oncology/BMT, University of Colorado School of Medicine & Children's Hospital Colorado, Aurora, CO 80045, USA.

Epigenomics
|May 6, 2015
PubMed
Summary

Epigenetic mechanisms are crucial in blood cancers, unlike other malignancies. Key epigenetic modifiers influence normal blood development and cancer, leading to targeted therapies currently in clinical trials.

Keywords:
DNMT3ADOT1LEZH2IDHMLLPRC1/2TET2WSHC1/NSD2/MMSETepigeneticsleukemia

More Related Videos

Combining Intravital Fluorescent Microscopy IVFM with Genetic Models to Study Engraftment Dynamics of Hematopoietic Cells to Bone Marrow Niches
11:06

Combining Intravital Fluorescent Microscopy IVFM with Genetic Models to Study Engraftment Dynamics of Hematopoietic Cells to Bone Marrow Niches

Published on: March 21, 2017

8.4K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.2K

Related Experiment Videos

Last Updated: Apr 13, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K
Combining Intravital Fluorescent Microscopy IVFM with Genetic Models to Study Engraftment Dynamics of Hematopoietic Cells to Bone Marrow Niches
11:06

Combining Intravital Fluorescent Microscopy IVFM with Genetic Models to Study Engraftment Dynamics of Hematopoietic Cells to Bone Marrow Niches

Published on: March 21, 2017

8.4K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.2K

Area of Science:

  • Hematology
  • Cancer Biology
  • Epigenetics

Background:

  • Genetic aberrations are less frequent in hematologic malignancies compared to other cancers, suggesting a significant role for epigenetic alterations.
  • Epigenetic modifiers are vital for normal hematopoietic stem cell development, self-renewal, and differentiation.
  • Alterations in these epigenetic modifiers are implicated in the development of hematopoietic malignancies.

Purpose of the Study:

  • To review and compare the roles of key DNA and histone modifying enzymes in normal hematopoietic development and hematologic malignancies.
  • To highlight the involvement of specific epigenetic modifiers such as DNMT3A, TET2, IDH1/2, MLL1/4, DOT1L, and PRC1/2.

Main Methods:

  • Literature review focusing on epigenetic mechanisms in hematopoiesis and cancer.
  • Comparative analysis of the functions of specific epigenetic enzymes in normal and malignant hematopoiesis.
  • Examination of therapeutic strategies targeting epigenetic modifiers.

Main Results:

  • Several key epigenetic modifiers, including DNMT3A, TET2, IDH1/2, MLL1/4, DOT1L, and PRC1/2, are critical in both normal blood development and hematopoietic cancers.
  • Understanding the biological mechanisms of these enzymes has paved the way for targeted therapies.
  • Therapies targeting mutant IDH1/2, DOT1L, and EZH2 are in clinical trials.

Conclusions:

  • Epigenetic dysregulation is a central feature of hematologic malignancies.
  • Targeting specific epigenetic modifiers offers a promising therapeutic avenue for blood cancers.
  • Ongoing clinical trials are evaluating the efficacy of these novel epigenetic therapies.